JB Chemicals Q4 Results Review: Dolat Capital Maintains 'Buy' Post Inline Earnings, Sees 27% Upside

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

JB Chemicals and Pharmaceuticals Ltd.’s focus on the domestic chronic portfolio and contract manufacturing organisation segment, combined with traction in export formulations, provides strong earnings visibility, superior cash flows, and return ratios.

We maintain our ‘Buy’ rating with a revised target price of Rs 2,081 at 32 times FY27 P/E adjusted for ESOP and amortization.

Key risks: Price control on any drugs and higher input cost.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.